These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18676406)

  • 1. Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
    Teunissen CE; Killestein J; Kragt JJ; Polman CH; Dijkstra CD; Blom HJ
    J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1349-53. PubMed ID: 18676406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma homocysteine levels in multiple sclerosis.
    Ramsaransing GS; Fokkema MR; Teelken A; Arutjunyan AV; Koch M; De Keyser J
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):189-92. PubMed ID: 16421120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
    Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
    Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis.
    Wilczak N; Ramsaransing GS; Mostert J; Chesik D; De Keyser J
    Mult Scler; 2005 Feb; 11(1):13-5. PubMed ID: 15732261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis.
    Oliveira SR; Flauzino T; Sabino BS; Kallaur AP; Alfieri DF; Kaimen-Maciel DR; Morimoto HK; de Almeida ERD; Lozovoy MAB; Reiche EMV; Dichi I; Simão ANC
    Metab Brain Dis; 2018 Oct; 33(5):1393-1399. PubMed ID: 29797117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.
    Yun JW; Cvek U; Kilgore PCSR; Tsunoda I; Omura S; Sato F; Zivadinov R; Ramanathan M; Minagar A; Alexander JS
    Life Sci; 2019 Jul; 229():116-123. PubMed ID: 31082401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
    de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
    Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
    Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
    Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
    Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
    Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
    J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
    Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
    Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
    Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum lactate as a novel potential biomarker in multiple sclerosis.
    Amorini AM; Nociti V; Petzold A; Gasperini C; Quartuccio E; Lazzarino G; Di Pietro V; Belli A; Signoretti S; Vagnozzi R; Lazzarino G; Tavazzi B
    Biochim Biophys Acta; 2014 Jul; 1842(7):1137-43. PubMed ID: 24726946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated HSP27 levels during attacks in patients with multiple sclerosis.
    Ce P; Erkizan O; Gedizlioglu M
    Acta Neurol Scand; 2011 Nov; 124(5):317-20. PubMed ID: 21208199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
    J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.